The FDA does not decide whether or not to stop the
Post# of 148166
Statistical significance is reached at approximately 22/23. Where did you get your numbers?
Regeneron and Lilly are NOT for severe/critical. They are for mild/moderate early stage disease only and they are NOT competition. Also, they have very few doses available.